Global Microscopic Polyangiitis (MPA) Drug Pipeline Trends 2019: Discovery, Pre-clinical, Clinical, In Approval Therapeutics, Companies and Markets
High levels of pipeline activity are being observed in Microscopic Polyangiitis (MPA) treatment during 2019. Clinical development activities are being undertaken by more than 5 companies including Celltrion Inc, ChemoCentryx Inc, InflaRx Gmbh, Sandoz International GmbH, Teijin Pharma Ltd and others.
A Significant contribution to the Microscopic Polyangiitis (MPA) pipeline is being observed from emerging companies opting for new approaches to clinical development strategy. The early stage and late-stage Microscopic Polyangiitis (MPA) pipeline included 6 compounds, driven by increasing number of targeted therapies. Progress is being made in accelerating compounds into advanced stages. However, fluctuating trends are being observed in average duration across three phases.
Increased understanding of underlying causes of Microscopic Polyangiitis (MPA) condition and increased access to investments is encouraging growth of Microscopic Polyangiitis (MPA) drug pipeline. However, despite high levels of pipeline activity, increasing clinical trial costs and decreasing drug approval rates is requiring companies to focus more on understanding clinical development pipeline compounds.
The research study is structured to provide clear and actionable insights into Microscopic Polyangiitis (MPA) drug pipeline for companies to optimize spending levels by understanding competition, their pipeline products and prospect of further advances over the next few years.
The report addresses the discovery, research and pre-clinical stage active Microscopic Polyangiitis (MPA) therapeutic candidates. Further, drugs in clinical stage including phase 1, phase 2, phase 3 and pre-registration phases are also analyzed.
The current report examines the current Microscopic Polyangiitis (MPA) pipeline along with current development status, regulatory progress, mechanism of action, route of administration, collaborating companies, sponsors, molecule type, and research/discovery details.
In addition to drug overview, recent developments, the report also provides mechanism of action, Pre-clinical trial details and Clinical trial details for each of the drug candidates of Microscopic Polyangiitis (MPA). Further, orphan drug status, fast track designation, grants awarded and other special status for Microscopic Polyangiitis (MPA) pipeline compounds are also included.
This study was produced independently by VPAResearch from our proprietary databases, primarily to assist users to develop in-depth understanding of 2019 Microscopic Polyangiitis (MPA) pipeline and formulate effective research and development strategies.
RESEARCH METHODOLOGY
Our integrated data reports are built through robust research methodology to ensure our users can build on the insights and data accuracy for their expansion plans. Both primary and secondary research methods are used with stringent quality checks at each stage to evaluate trends, analysis and forecasts.
Scope of the Research
Microscopic Polyangiitis (MPA) Pipeline candidates-
A Significant contribution to the Microscopic Polyangiitis (MPA) pipeline is being observed from emerging companies opting for new approaches to clinical development strategy. The early stage and late-stage Microscopic Polyangiitis (MPA) pipeline included 6 compounds, driven by increasing number of targeted therapies. Progress is being made in accelerating compounds into advanced stages. However, fluctuating trends are being observed in average duration across three phases.
Increased understanding of underlying causes of Microscopic Polyangiitis (MPA) condition and increased access to investments is encouraging growth of Microscopic Polyangiitis (MPA) drug pipeline. However, despite high levels of pipeline activity, increasing clinical trial costs and decreasing drug approval rates is requiring companies to focus more on understanding clinical development pipeline compounds.
The research study is structured to provide clear and actionable insights into Microscopic Polyangiitis (MPA) drug pipeline for companies to optimize spending levels by understanding competition, their pipeline products and prospect of further advances over the next few years.
The report addresses the discovery, research and pre-clinical stage active Microscopic Polyangiitis (MPA) therapeutic candidates. Further, drugs in clinical stage including phase 1, phase 2, phase 3 and pre-registration phases are also analyzed.
The current report examines the current Microscopic Polyangiitis (MPA) pipeline along with current development status, regulatory progress, mechanism of action, route of administration, collaborating companies, sponsors, molecule type, and research/discovery details.
In addition to drug overview, recent developments, the report also provides mechanism of action, Pre-clinical trial details and Clinical trial details for each of the drug candidates of Microscopic Polyangiitis (MPA). Further, orphan drug status, fast track designation, grants awarded and other special status for Microscopic Polyangiitis (MPA) pipeline compounds are also included.
This study was produced independently by VPAResearch from our proprietary databases, primarily to assist users to develop in-depth understanding of 2019 Microscopic Polyangiitis (MPA) pipeline and formulate effective research and development strategies.
RESEARCH METHODOLOGY
Our integrated data reports are built through robust research methodology to ensure our users can build on the insights and data accuracy for their expansion plans. Both primary and secondary research methods are used with stringent quality checks at each stage to evaluate trends, analysis and forecasts.
Scope of the Research
Microscopic Polyangiitis (MPA) Pipeline candidates-
- Pre-clinical Phase: Discovery, research, pre-clinical
- Early Phase: Phase 1 and Phase 2 Microscopic Polyangiitis (MPA) drugs
- Late phase: Phase 3 and in-approval Microscopic Polyangiitis (MPA) drugs
- Company overview
- Snapshot
- Microscopic Polyangiitis (MPA) therapeutic treatment activities
- Snapshot
- Drug Name
- Alternative Names
- Company
- Originator
- Phase
- Molecule Type
- Orphan Drug Status
- Drug Overview
- Mechanism of Action
- Current Status
- Trial Details
- Pre-clinical trials for each drug candidate
- Clinical trials for each drug candidate
1 TABLE OF CONTENTS
1.1 List of Tables
1.2 List of Figures
2 EXECUTIVE SUMMARY
2.1 Microscopic Polyangiitis (MPA)- Disease Overview
2.2 Microscopic Polyangiitis (MPA)- Pipeline Snapshot
2.3 Microscopic Polyangiitis (MPA)- Pipeline Drugs by Phase
2.4 Microscopic Polyangiitis (MPA)- Pipeline Drugs by Company
2.5 Microscopic Polyangiitis (MPA)- Pipeline Drugs by Mechanism of Action
3 COMPANY WISE PIPELINE ANALYSIS
3.1 Celltrion Inc Microscopic Polyangiitis (MPA) Drug Pipeline, H2- 2019
3.2 ChemoCentryx Inc Microscopic Polyangiitis (MPA) Drug Pipeline, H2- 2019
3.3 InflaRx Gmbh Microscopic Polyangiitis (MPA) Drug Pipeline, H2- 2019
3.4 Sandoz International GmbH Microscopic Polyangiitis (MPA) Drug Pipeline, H2- 2019
3.5 Teijin Pharma Ltd Microscopic Polyangiitis (MPA) Drug Pipeline, H2- 2019
3.6 TTY Biopharm Company Ltd Microscopic Polyangiitis (MPA) Drug Pipeline, H2- 2019
4 PHASE 1 PIPELINE DRUG DETAILS
4.1 Microscopic Polyangiitis (MPA)- Phase 1 Drug Details
4.2 Microscopic Polyangiitis (MPA)- Phase 1 Drug Overview
4.3 Microscopic Polyangiitis (MPA)- Phase 1 Mechanism of Action
4.4 Current Status
4.5 Trial Details
5 PHASE 2 PIPELINE DRUG DETAILS
5.1 Microscopic Polyangiitis (MPA)- Phase 2 Drug Details
5.2 Microscopic Polyangiitis (MPA)- Phase 2 Drug Overview
5.3 Microscopic Polyangiitis (MPA)- Phase 2 Mechanism of Action
5.4 Current Status
5.5 Trial Details
6 PHASE 3 PIPELINE DRUG DETAILS
6.1 Microscopic Polyangiitis (MPA)- Phase 3 Drug Details
6.2 Microscopic Polyangiitis (MPA)- Phase 3 Drug Overview
6.3 Microscopic Polyangiitis (MPA)- Phase 3 Drug Mechanism of Action
6.4 Current Status
6.5 Trial Details
7 PRE-CLINICAL PHASE PIPELINE DRUG DETAILS
7.1 Microscopic Polyangiitis (MPA)- Pre-clinical Phase Drug Details
7.2 Microscopic Polyangiitis (MPA)- Pre-clinical Phase Drug Overview
7.3 Microscopic Polyangiitis (MPA)- Pre-clinical Phase Drug Mechanism of Action
7.4 Current Status
7.5 Trial Details
8 RECENT NEWS AND DEVELOPMENTS
9 APPENDIX
9.1 About VPAResearch
9.2 Sources and Research Methodology
1.1 List of Tables
1.2 List of Figures
2 EXECUTIVE SUMMARY
2.1 Microscopic Polyangiitis (MPA)- Disease Overview
2.2 Microscopic Polyangiitis (MPA)- Pipeline Snapshot
2.3 Microscopic Polyangiitis (MPA)- Pipeline Drugs by Phase
2.4 Microscopic Polyangiitis (MPA)- Pipeline Drugs by Company
2.5 Microscopic Polyangiitis (MPA)- Pipeline Drugs by Mechanism of Action
3 COMPANY WISE PIPELINE ANALYSIS
3.1 Celltrion Inc Microscopic Polyangiitis (MPA) Drug Pipeline, H2- 2019
3.2 ChemoCentryx Inc Microscopic Polyangiitis (MPA) Drug Pipeline, H2- 2019
3.3 InflaRx Gmbh Microscopic Polyangiitis (MPA) Drug Pipeline, H2- 2019
3.4 Sandoz International GmbH Microscopic Polyangiitis (MPA) Drug Pipeline, H2- 2019
3.5 Teijin Pharma Ltd Microscopic Polyangiitis (MPA) Drug Pipeline, H2- 2019
3.6 TTY Biopharm Company Ltd Microscopic Polyangiitis (MPA) Drug Pipeline, H2- 2019
4 PHASE 1 PIPELINE DRUG DETAILS
4.1 Microscopic Polyangiitis (MPA)- Phase 1 Drug Details
4.2 Microscopic Polyangiitis (MPA)- Phase 1 Drug Overview
4.3 Microscopic Polyangiitis (MPA)- Phase 1 Mechanism of Action
4.4 Current Status
4.5 Trial Details
5 PHASE 2 PIPELINE DRUG DETAILS
5.1 Microscopic Polyangiitis (MPA)- Phase 2 Drug Details
5.2 Microscopic Polyangiitis (MPA)- Phase 2 Drug Overview
5.3 Microscopic Polyangiitis (MPA)- Phase 2 Mechanism of Action
5.4 Current Status
5.5 Trial Details
6 PHASE 3 PIPELINE DRUG DETAILS
6.1 Microscopic Polyangiitis (MPA)- Phase 3 Drug Details
6.2 Microscopic Polyangiitis (MPA)- Phase 3 Drug Overview
6.3 Microscopic Polyangiitis (MPA)- Phase 3 Drug Mechanism of Action
6.4 Current Status
6.5 Trial Details
7 PRE-CLINICAL PHASE PIPELINE DRUG DETAILS
7.1 Microscopic Polyangiitis (MPA)- Pre-clinical Phase Drug Details
7.2 Microscopic Polyangiitis (MPA)- Pre-clinical Phase Drug Overview
7.3 Microscopic Polyangiitis (MPA)- Pre-clinical Phase Drug Mechanism of Action
7.4 Current Status
7.5 Trial Details
8 RECENT NEWS AND DEVELOPMENTS
9 APPENDIX
9.1 About VPAResearch
9.2 Sources and Research Methodology
